Carlo Genova· @CarloGenova5 · X·· 14 小时前评分70
正文 · 原文
Standing ovation at #ESMO2026 for DELLPHI-305. It is heart-warming to see a meaningful survival advantage in ED-SCLC.
105 浏览 · 1 赞 · 1 转发 · 0 回复
会议摘要
LBA3按 Presidential Symposium I 对上
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org来源：Carlo Genova · x.com